Nasus Pharma (NSRX) Life Sciences Virtual Investor Forum summary

Technology overview

• Nasax technology enables precise control of particle size and shape for optimal nasal absorption.

• Powder formulation allows deep penetration into the nasal cavity, enhancing drug uptake.

• Needle-free, dry powder design improves convenience, shelf life, and patient compliance.

Lead product and clinical progress

• Lead product is an intranasal powder epinephrine (NS002) for anaphylaxis, entering phase III in Q4 2024.

• Phase II studies showed faster and higher absorption than EpiPen, with superior onset of action.

• Product maintains efficacy even under severe nasal congestion.

Market landscape and differentiation

• Anaphylaxis market is large and growing due to rising allergy incidence, with a shift toward needle-free products.

• Powder formulation offers faster absorption and higher efficacy compared to liquid and sublingual competitors.

• Superior onset of action positions the product as a potential first-line therapy.